Passage Bio, Inc. (PASG) - Forward P/S Multiple
Insurance fund reimbursement for rare brain pathology therapies creates the financial foundation for Passage Bio, Inc. (PASG). The projected P/S multiple reflects market expectations, where the mark characterizes this parameter. Passage Bio, Inc. (PASG) relies on AAV-vector gene delivery to treat orphan diseases, yet intense investor pressure is forcing the company to accelerate trials in competition with global players.
Comprehensive metric breakdowns and analytics for passagebio.com (PASG)
- stock price and consensus target price:
- market capitalization indicators:
- issuer book value statistics:
- business debt structure and liquidity details:
Total Debt to Equity Ratio Passage Bio, Inc.|PASG - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Passage Bio|PASG - Company Total Debt Obligations|Debt to Book Capitalization Ratio Passage Bio, Inc.|PASG - Company Long-Term Indebtedness|Company Short-Term Debts Passage Bio|Quick Liquidity Indicator passagebio.com
- financial results and valuation multiples details:
PASG - Net Financial Result|Expected Profit Passage Bio, Inc.|PASG - Market Cap to Net Income|Forward P/E Multiple Passage Bio|PASG - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Passage Bio, Inc.|PASG - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Passage Bio|PASG - Net earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months passagebio.com|PASG - Earnings per share growth this year|Earnings growth forecast for next year Passage Bio, Inc.
- sales volume and revenue indicators:
Comprehensive company analysis:PASG (Passage Bio Corp)
To protect capital from volatility, it is crucial for investors to understand the extent to which the market capitalization of Passage Bio, Inc. (PASG) is justified by future sales expectations. The global expansion of CNS gene therapy via AAV vectors drives the projected P/S trend, which measures the market's willingness to pay a premium for future revenue; a sharp rise in the line signals optimism regarding the commercial capture of the neuropharma sector, but warns of the risk of overvalued assets.
Competitor analysis for Passage Bio, Inc.
Biogen - Forward Price-to-Revenue Multiple|Forward Price to Sales NBIX|Regencell - Forward P/S Multiple|AXSM: Price-to-Projected Revenue Ratio|ACAD: Forward P/S Multiple|XENE - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Viking Therapeutics, Inc.|Market Cap to Future Revenue Ratio Supernus Pharmaceuticals, Inc. SUPN|Forward Price-to-Revenue Multiple CPRX (Catalyst Pharmaceuticals Inc)|DNLI (Denali Corp) - Forward Price to Sales|Forward P/S Multiple HRMY (Harmony Biosciences)|Market Cap to Expected Sales Ratio biohavenpharma.com (BHVN)|AMLX - Price-to-Projected Revenue Ratio|TRVI (Trevi Therapeutics Inc) - Market Cap to Projected Revenue|PRAX: Forward P/S Multiple|Forward Price-to-Revenue Multiple Anavex Life Sciences Corp|Forward Price-to-Revenue Multiple CBLL|Prothena Corporation (PRTA) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Alector, Inc. (ALEC)|ANNX: Future Price to Revenue|Forward P/S Multiple OMER (Omeros)|Forward P/S Multiple Neurogene Therapeutics NGNE|ACIU - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio voyagertherapeutics.com VYGR|NMRA: Forward P/S Multiple|Projected Price to Revenue Scilex Holding SCLX|Price-to-Projected Revenue Ratio Tevogen Bio Holdings, Inc.|Market Cap to Projected Revenue ACOG (Alpha Cognition Corp)|Forward P/S Multiple CGTX|IKT - Market Cap to Future Revenue Ratio|Cassava Sciences - Forward Price-to-Revenue Multiple|Forward P/S Multiple Assertio Holdings ASRT|COYA - Price-to-Projected Revenue Ratio|Forward Price to Sales VTGN (Vistagen Therapeutics)|ovidrx.com (OVID) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio acumenpharm.com (ABOS)|Price-to-Projected Revenue Ratio CervoMed|Alterity Therapeutics Ltd - Future Price to Revenue|Forward P/S Multiple CLNN|Forward P/S Multiple pepgen.com (PEPG)|Price-to-Projected Revenue Ratio Jupiter Neurosciences Inc JUNS|Market Cap to Expected Sales Ratio relmada.com (RLMD)|ANVS - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Grace Therapeutics, Inc. GRCE|AIFF: Forward P/S Multiple|Klotho Neurosciences (KLTO) - Forward P/S Multiple|NRSN (NeuroSense Therapeutics Ltd) - Forward P/S Multiple|RVPH - Projected Price to Revenue|Forward P/S Multiple MTVA|NRXS - Market Cap to Future Revenue Ratio|Helius Medical Technologies - Forward Price-to-Revenue Multiple|Forward Price to Sales NEUP|Minerva Neurosciences - Forward P/S Multiple|ATHA: Price-to-Projected Revenue Ratio|ADXN: Forward P/S Multiple|ALZN - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Cyclerion Therapeutics Inc.|Market Cap to Future Revenue Ratio Protagenic PTIX|Forward Price-to-Revenue Multiple KTTA (Pasithea Therapeutics)|CRGT (cortigent.com) - Forward Price to Sales|Forward P/S Multiple ATXI (Avenue Therapeutics, Inc.)|Market Cap to Expected Sales Ratio Brainstorm Cell Therapeutics Inc. (BCLI)|CARA - Price-to-Projected Revenue Ratio|CHRO (Chromocell) - Market Cap to Projected Revenue|ELYM: Forward P/S Multiple|Forward Price-to-Revenue Multiple Intra-Cellular Therapies, Inc.|Forward Price-to-Revenue Multiple LBPH|Marinus Pharmaceuticals Inc (MRNS) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio NKGen (NKGN)|NRBO: Future Price to Revenue|Forward P/S Multiple SAGE (Sage Therapeutics, Inc.)|Forward P/S Multiple synaptogen.com SNPX|TRVN - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Vigil Neuroscience VIGL|WENA: Forward P/S Multiple|Projected Price to Revenue Cerevel Corp CERE
